Immune gene expression in head and neck squamous cell carcinoma patients
European Journal of Cancer2019Vol. 121, pp. 210–223
Citations Over TimeTop 10% of 2019 papers
Charlotte Lecerf, Maud Kamal, Sophie Vacher, Walid Chemlali, Anne Schnitzler, Claire Morel, Coraline Dubot, Emmanuelle Jeannot, Didier Meseure, Jerzy Klijanienko, Odette Mariani, Édith Borcoman, Valentin Calugaru, Nathalie Badois, A. Chillès, Maria Lesnik, S. Krhili, Olivier Choussy, Caroline Hoffmann, Eliane Piaggio, Ivan Bièche, Christophe Le Tourneau
Abstract
OX40L and PDGFRB overexpression was associated with poor outcomes, whereas PD-1 overexpression was associated with good prognosis in patients with HNSCC treated with primary surgery, suggesting their relevance as potential prognostic biomarkers and major therapeutic targets.
Related Papers
- → A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes(2016)117 cited
- → 4CPS-072 Comparison of immune checkpoint inhibitors (nivolumab, pembrolizumab, atézolizumab and durvalumab) in the treatment of non-small cell lung cancer: tolerance and financial impact(2020)1 cited
- → Porównanie pośrednie wyników leczenia chorych na zaawansowane/przerzutowe czerniaki za pomocą niwolumabu lub pembrolizumabu – analiza wieloośrodkowa(2020)1 cited
- → Profiling of immune related adverse events from nivolumab or pembrolizumab monotherapy in advanced non-small cell lung cancer in real world(2018)